Institutional members access full text with Ovid®

Share this article on:

New Drug for All

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: March 2012 - Volume 112 - Issue 3 - p 23,24
doi: 10.1097/
Drug Watch
  • Asparaginase Erwinia chrysanthemi (Erwinaze) is a new drug approved for the treatment of acute lymphoblastic leukemia (ALL) in patients allergic to the ALL drugs that are derived from Escherichia coli.
  • Erwinaze carries risks of anaphylaxis, severe or hemorrhagic pancreatitis, coagulation abnormalities, and hyperglycemia that can be permanent and require insulin therapy.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2012 Lippincott Williams & Wilkins, Inc.